• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
TLX
Click for more information
3.03% $19.18

TELIX PHARMACEUTICALS LIMITED - News & Media

Market Cap $6.418B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The... Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).More

Articles & Videos

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Telix has announced its prostate cancer imaging drug Illuccix won't be negatively impacted by proposed changes to the US medicare system.

11 Jul 2024 13:29 (AEST)

Telix dips as pharma giant abandons US IPO for NASDAQ listing – despite record run

International plans for Telix – proudly boasting its intentions to list on the NASDAQ for a while now – have come to an anticlimactic end.

14 Jun 2024 10:54 (AEST)

Telix kicks off $300M NASDAQ IPO offer, backed by Morgan Stanley

Morgan Stanley and Jefferies are among the managers overseeing Telix Pharma's (ASX:TLX) freshly commenced US IPO process.

06 Jun 2024 09:59 (AEST)

Telix testing shows efficacy of anti-prostate cancer therapy

Telix Pharmaceuticals Ltd has picked up some positive results in testing of its anti-prostate cancer therapy.

31 May 2024 13:45 (AEST)

Telix gets its foot in the FDA door bringing prostate cancer detection closer to neglected Americans

Telix Pharmaceuticals has submitted a new drug application to the United States Food and Drug Administration for TLX007-CDx,

27 May 2024 09:43 (AEST)

Telix Pharma gears up to launch US IPO

Telix Pharmaceuticals has announced it's working with Morgan Stanley to list depository shares on the NASDAQ.

20 May 2024 08:57 (AEST)

Telix Pharmaceuticals granted US-FDA fast track designation for brain cancer detection

Telix Pharmaceuticals has been granted Fast Track designation by the FDA for its brain cancer imaging software; TLX101-CDx

16 Apr 2024 12:42 (AEST)

Telix Pharmaceuticals finalises acquisition of IsoTherapeutics

Telix Pharmaceuticals (ASX:TLX) has acquired one of its service suppliers - IsoTherapeutics Group - in a deal worth more than A$20 million.

09 Apr 2024 10:42 (AEST)

Telix Boosts U.S. Presence with IsoTherapeutics Acquisition

Melbourne-based Telix Pharmaceuticals (ASX: TLX) has sealed the deal to acquire IsoTherapeutics Group, LLC

27 Feb 2024 11:14 (AEDT)

Telix Pharmaceuticals submits BLA for Zircaix for imaging of kidney cancer

Telix Pharmaceuticals (ASX:TLX) has submitted its BLA to the US FDA for its investigational PET imaging agent Zircaix for imaging of kidney cancer.

19 Dec 2023 12:42 (AEDT)



(20min delay)
Last
$19.18 		Change
-0.600(3.03%) 		Mkt cap ! $6.418B
Open High Low Value Volume
$18.90 $19.21 $18.04 $51.74M 2.756M

Buyers (Bids)

No. Vol. Price($)
2 710 $19.15
 

Sellers (Offers)

Price($) Vol. No.
$19.20 7058 2
View Market Depth
Last trade - 16.10pm 23/08/2024 (20 minute delay) ?
Last
$19.11 		  Change
-0.600 ( 3.41 %)
Open High Low Volume
$18.87 $19.21 $18.04 542421
Last updated 15.59pm 23/08/2024 ?
TLX (ASX) Chart

Top Stories

The business of sport: Warren Tredrea's take on this week's news

Former Port Adelaide AFL star – turned media personality – Warren Tredrea and co-host Jack Hudson explore money in sport.
Raiden gears up for exploration in final quarter of 2024 Raiden Resources Ltd - which is exploration for a multiplicity of minerals in the Pilbara region of WA - is looking ahead to a busy schedule.
The Rising Tide: How institutional adoption is shaping the future of crypto This year's institutional demand for Bitcoin supports stability & credibility for the asset class. We look at what's happened since crypto ETFs were approved in the US & what that means for Australian investors.
IPH raises $100M to buy up Canadian IP firm Bereskin & Parr IPH Ltd has raised $100 million in an institutional placement to support the acquisition, while also launching a share purchase plan.
How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign Strategic Energy Resources is 4 holes into a 40-hole RC drill campaign at its Achilles 1 copper-gold target in the Cobar Basin of NSW.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.